Skip to main content
Log in

Pharmacokinetics and side-effects of clonidine

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

A single oral dose of clonidine 300 µg was administered to 8 healthy, normotensive subjects and the time course of its plasma concentrations was followed for 24 h. The plasma concentration of clonidine rose to a peak of 1.17±0.12 ng/ml at about 2 h: the absorption half-life was 0.6±0.2 h. Elimination followed first order kinetics with a half-life of 7.7±2.0 h. The correlation between the two most common side-effects of clonidine, sedation and dryness of the mouth, with the time course of its plasma concentrations was highly significant, p<0.01. All the subjects complained of severe sedation. During continuous administration of clonidine (75 µg t.i.d.) for one week a steady state serum level of 0.30–0.35 ng/ml was achieved. One 75 µg tablet of clonidine raised the serum level to about 0.69±0.13 ng/ml in two hours. After cessation of dosing, the serum level declined with a half-life of 7.5±1.5 h. The urinary excretion of unchanged clonidine was found to be about onethird of the administered dose in 24 h during continuous administration and in the first 24 h after the single oral dose.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kobinger, W., Walland, A.: Investigations into the mechanism of the hypotensive effect of 2-(2,6-dichlorophenylamino)-2-imidazoline HCl. Europ. J. Pharmacol.2, 155–162 (1967)

    Google Scholar 

  2. Bousquet, P.: Localisation of the central cardiovascular action of the clonidine. Brit. J. Pharmacol.49, 573–579 (1973)

    Google Scholar 

  3. Zaimis, E.: On the pharmacology of Catapress (St. 155). In: Catapress in hypertension (ed. M.E. Conolly), pp 222–226. London: Butterworth 1970

    Google Scholar 

  4. Conolly, M. E., Briant, R. H., George, C. F., Dollery, C. T.: A crossover comparison of clonidine and metyldopa in hypertension. Europ. J. clin. Pharmacol.4, 222–227 (1972)

    Google Scholar 

  5. Putzeys, M. R., Hoobier, S. W.: Comparison of clonidine and methyldopa on blood pressure and side-effects in hypertensive patients. Amer. Heart J.83, 464–468 (1972)

    Google Scholar 

  6. Rand, M. J., Rush, M., Wilson, S.: Some observations on the inhibition of salivation by ST 155. Europ. J. Pharmacol.5, 168–172 (1969)

    Google Scholar 

  7. Laverty, R., Taylor, K. M.: Behavioural and biochemical effects of 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride (ST 155) on the central nervous system. Brit. J. Pharmacol.35, 253–264 (1969)

    Google Scholar 

  8. Dollery, C. T., Davies, D. S., Draffan, G. H., Dargie, H. J., Pean, C. R., Reid, J. L., Clare, R. A., Murray, S.: Clinical pharmacology and pharmacokinetics of clonidine. Clin. Pharmacol. Ther.19, 11–17 (1976)

    Google Scholar 

  9. Cho, A. K., Curry, S.: The physiological disposition of 2-(2,6-dichlorophenylamino)-2-imidazoline. Biochem. Pharmacol.18, 511–520 (1969)

    Google Scholar 

  10. Rehbinder, D.: The metabolism of clonidine. In: Catapress in hypertension (ed. M. E. Conolly) pp 227–233. London: Butterworth 1970

    Google Scholar 

  11. Draffan, G. H., Clare, R. A., Murray, S., Bellward, G. D., Davies, D. S., Dollery, C. T.: The determination of clonidine in human plasma. Proceedings of the Third International Symposium on Mass Spectrometry in Biochemistry and Medicine, Sardinia, Italy, June 1975

  12. Ehrhardt, J. D.: Métabolisme du catapressan. Action hypotensive du 4-hydroxycatapressan. Thérapie27, 947–954 (1972)

    Google Scholar 

  13. Edlund, P-O., Paalzow, L. K.: Pharmakokinetics of clonidine determined by gas liquid chromatography. XV Scandinavian Congress of Physiology, Århus, abstr. 170, p. 116 (1976)

  14. Rehbinder, D., Deckers, W.: Untersuchungen zur Pharmakokinetik und zum Metabolismus des 2-(2,6-Dichlorphenylamino)-2-imidazolin-hydrochlorid (St 155). Arzneim. Forschung19, 169–176 (1969)

    Google Scholar 

  15. Bock, K. D., Heimsoth, V., Merguet, P., Shoenermark, J.: Klinische und Klinische-experimentelle Untersuchungen mit einer neuen blutdrucksenkenden Substanz, Dichlorphenylaminoimidazolin. Dtsch. Med. Wschr.91, 1761–1772 (1966)

    Google Scholar 

  16. Michel, D., Zimmermann, W., Nasschi, A., Seraphim, P.: Erste Beobachtungen über einen antihypertensiven Effet von 2-(2,6-dichlorophenylamino)-2-imidazolin-hydrochloride am Menschen. Dtsch. Med. Wschr.91, 1540–1547 (1966)

    Google Scholar 

  17. NG, D. D., Phelau, E. L., McGregor, D. D., Laverty, R., Taylor, K. M., Sir Smirk, H.: Properties of Catapress, a new hypotensive drug: A preliminary report. New Zealand med. J.66, 864–870 (1967)

    Google Scholar 

  18. Raftos, J., Bauer, G. E., Lewis, R. G. et al.: Clonidine in the treatment of severe hypertension. Med. J. Aust.1, 786–793 (1973)

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Keränen, A., Nykänen, S. & Taskinen, J. Pharmacokinetics and side-effects of clonidine. Eur J Clin Pharmacol 13, 97–101 (1978). https://doi.org/10.1007/BF00609752

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00609752

Key words

Navigation